IGF1R and lymphedema: The favorable safety profile of targeting IGF1R raises the possibility of using linsitinib or other IGF1R inhibitors, including IGF1R monoclonal antibodies,48 to treat secondary lymphedema in the clinic, potentially for long periods of time.